PMID: 11322710Apr 27, 2001Paper

Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study

Sleep
O LarrosaD Garcia-Borreguero

Abstract

To investigate potential stimulant and anticataplectic effects of 10 mg reboxetine in patients diagnosed with narcolepsy. 12 patients were treated for a 2-week period with 10 mg reboxetine under open conditions. The dosage of reboxetine was gradually increased between Day 1 and Day 9. Outcome parameters consisted of nightime polysomnography (PSG), Multiple Sleep Latency Test (MSLT), Epworth Sleepiness Scale (ESS), Visual Analog Scale for Sleepiness (VAS), Ullanlinna Narcolepsy Scale (UNS), and the Beck Depression Inventory (BDI). Sleep Disorders Clinic at a University Hospital. 12 patients meeting ICSD-criteria for narcolepsy. Pharmacological treatment with reboxetine. Following treatment for two-weeks, a significant improvement in daytime sleepiness could be observed, as reflected by a mean decrease of 48.6% on the Epworth Sleepiness Scale and a mean increase of 54.7% in sleep latency on the MSLT. Furthermore, a significant reduction in the cataplexy subscore of the Ullanlinna Narcolepsy Scale and in REM-sleep was found. Our results suggest that reboxetine exerts stimulant and anticataplectic effects in narcolepsy. Contrary to previous thinking, by which stimulant action would require dopaminergic facilitation, noradrenergic m...Continue Reading

Citations

Jan 31, 2003·Annals of Neurology·Thomas E Scammell
Jun 7, 2006·Annals of Medicine·Yves Dauvilliers, Mehdi Tafti
Apr 27, 2017·Expert Opinion on Pharmacotherapy·Ulf Kallweit, Claudio L Bassetti
May 29, 2019·Expert Opinion on Pharmacotherapy·Vivien C Abad
Sep 22, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M BilliardUNKNOWN EFNS Task Force
Mar 11, 2005·Expert Opinion on Pharmacotherapy·Michael J Thorpy
Nov 10, 2007·Current Opinion in Neurology·Susan Keam, Matthew C Walker
Mar 26, 2013·Expert Opinion on Pharmacotherapy·Régis Lopez, Yves Dauvilliers
Jul 12, 2020·Current Neurology and Neuroscience Reports·Arpita ParmarIndra Narang
Apr 17, 2003·Drugs & Aging·Sangeeta S Chakravorty, David B Rye
Jun 4, 2014·Nature Reviews. Neurology·Yves DauvilliersJohn H Peever
Jul 11, 2019·Sleep & Breathing = Schlaf & Atmung·Christian FranceschiniGiuseppe Plazzi
Jan 19, 2020·CNS Drugs·Michael J Thorpy
Aug 9, 2020·Nature and Science of Sleep·Emily C BarkerKatherine M Sharkey
Feb 7, 2008·The Cochrane Database of Systematic Reviews·L VignatelliL Candelise
Apr 23, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Christian FranceschiniGiuseppe Plazzi
Jun 27, 2021·Journal of Sleep Research·Claudio L A BassettiGert J Lammers
Jun 27, 2021·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Claudio L A BassettiGert J Lammers
Aug 18, 2021·Expert Opinion on Therapeutic Targets·Marieke Vringer, Birgitte Rahbek Kornum

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.